<?xml version="1.0" encoding="UTF-8"?>
<results title="drug">
 <result pre="use as an arterial thromboembolic prophylaxis agent in combination with" exact="aspirin" post="or warfarin.109 Dipyridamole has recently been shown to suppress"/>
 <result pre="arterial thromboembolic prophylaxis agent in combination with aspirin or warfarin.109" exact="Dipyridamole" post="has recently been shown to suppress human neutrophil and"/>
 <result pre="suppress human neutrophil and T-cell activation, upstream of cytokine effectors.58,110" exact="Dipyridamole" post="induces a type I interferon response, which is necessary"/>
 <result pre="vitro by inhibiting a critical viral replication complex.111,112 Administered orally," exact="dipyridamole" post="has a favorable safety profile, and a small clinical"/>
 <result pre="and safety of monoclonal antibody to human tumor necrosis factor" exact="alpha" post="in patients with sepsis syndrome. A randomized, controlled, double-blind,"/>
 <result pre="Engl J Med2014; 370: 2191â€&quot;2200.24835849 99BernardGRWheelerAPRussellJA, et al.The effects of" exact="ibuprofen" post="on the physiology and survival of patients with sepsis."/>
 <result pre="on the physiology and survival of patients with sepsis. The" exact="Ibuprofen" post="in Sepsis Study Group. N Engl J Med1997; 336:"/>
 <result pre="Engl J Med2016; 375: 534â€&quot;544.27232649 105CohenATSpiroTESpyropoulosAC; collab: MAGELLAN Steering Committee." exact="Rivaroxaban" post="for thromboprophylaxis in acutely ill medical patients. N Engl"/>
 <result pre="Inc.122019. 110MacatangayBJCJacksonEKAbebeKZ, et al.A randomized, placebo-controlled, pilot clinical trial of" exact="dipyridamole" post="to decrease HIV-associated chronic inflammation. J Infect Dis2020; 221:"/>
 <result pre="Pharmacother. 1984; 38: 412â€&quot;413.6084526 113LiuXLiZLiuS, et al.Potential therapeutic effects of" exact="dipyridamole" post="in the severely ill patients with COVID-19. Acta Pharm"/>
</results>
